Skip to content


Aqilion runs four innovative programs

The Aqilion team and network has extensive expertise and experience in inflammation. The company runs four innovative R&D programs. The Regulus program is the most advanced and a clinical Phase 1 study is planned to be initiated during the second half of 2022. The Girtab program is in preclinical stage and Alnitak and Polaris programs are in discovery phase.

All four in-house programs fit the collective experience of the Aqilion team and allow us to make optimal use of the expertise of our network and partners.